Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients - Takeaways - MDSpire

Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients

  • By

  • Hong-Thanh Nguyen

  • Minh-Duc Vu

  • Dinh-Dung Nguyen

  • Phuong-Nhung Dinh

  • Van-Quy Hoang

  • Linh-Trang Ngoc Bui

  • Dinh-Tuan Nguyen

  • Phuoc-Huy Do

  • Thi-Oanh Tong

  • Van-Hung Nguyen

  • Thu-Huong Thi Han

  • Sy-Tung Ha

  • Huy-Duong Do

  • Thanh-Ha Thi Ly

  • Viet-Nhan Nguyen

  • July 17, 2026

Share

  • 1

    Germline mutations in BRCA1 and BRCA2 are significant genetic risk factors for hereditary cancers, including breast, ovarian, and prostate cancers.

  • 2

    BRCA1/2 mutations disrupt DNA repair mechanisms, leading to increased genomic instability and a higher risk of various malignancies.

  • 3

    The study aims to evaluate the prevalence and spectrum of BRCA1/2 mutations among Vietnamese patients with selected cancer types using next-generation sequencing.

  • 4

    Patients were selected based on NCCN Guidelines, focusing on triple-negative breast cancer and high-grade serous ovarian cancer for BRCA1/2 testing.

  • 5

    This research addresses the knowledge gap regarding BRCA1/2 mutations in Vietnam, which is crucial for effective genetic counseling and targeted therapies.

Original Source(s)

Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients

  • by Hong-Thanh Nguyen, Minh-Duc Vu, Dinh-Dung Nguyen, Phuong-Nhung Dinh, Van-Quy Hoang, Linh-Trang Ngoc Bui, Dinh-Tuan Nguyen, Phuoc-Huy Do, Thi-Oanh Tong, Van-Hung Nguyen, Thu-Huong Thi Han, Sy-Tung Ha, Huy-Duong Do, Thanh-Ha Thi Ly, Viet-Nhan Nguyen

  • July 17, 2026

Related Content

Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review

Patient satisfaction and perioperative data after breast surgery in tumescent local anaesthesia

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer